Supplemental Digital Content 7: Ocular (Study Eye; ≥2% in any Group) and Non-ocular (≥5% in any Group) Adverse Events, Regardless of Study Drug Relationship, over 12 months (Safety set*)

	Ranibizumab 0.5 mg		vPDT	
Preferred term, n (%)	**Group I (VA stabilization) (n = 182)**	**Group II (disease activity) (n = 185)**	**Group III (with ranibizumab 0.5 mg from Month 3) (n = 75)**	**Group III (without ranibizumab 0.5 mg from Month 3) (n = 14)**
Ocular AEs, total	**52 (28.6)**	**55 (29.7)**	**23 (30.7)**	**4 (28.6)**
Conjunctival hemorrhage	8 (4.4)	14 (7.6)	2 (2.7)	0
Xerophthalmia	7 (3.8)	7 (3.8)	2 (2.7)	0
Eye pain	6 (3.3)	5 (2.7)	1 (1.3)	1 (7.1)
Eye swelling	3 (1.6)	1 (0.5)	1 (1.3)	1 (7.1)
Conjunctivitis	2 (1.1)	5 (2.7)	3 (4.0)	1 (7.1)
IOP increased	2 (1.1)	4 (2.2)	1 (1.3)	0
VA reduced	2 (1.1)	0	2 (2.7)	0
Eye pruritus	2 (1.1)	2 (1.1)	0	1 (7.1)
Metamorphopsia	1 (0.5)	1 (0.5)	0	1 (7.1)

Vision blurred	0	6 (3.2)	0	0
VA tests abnormal	3 (1.6)	3 (1.6)	3 (4.0)	0
Non-ocular AEs, total	**93 (51.1)**	**94 (50.8)**	**42 (56.0)**	**5 (35.7)**
Nasopharyngitis	17 (9.3)	20 (10.8)	8 (10.7)	1 (7.1)
URTI	14 (7.7)	12 (6.5)	6 (8.0)	0
Cough	5 (2.7)	10 (5.4)	5 (6.7)	0

*Consisted of all patients who received at least one application of study treatment and had at least one post-baseline safety assessment.

A patient with multiple occurrences of an AE under one treatment is counted only once in the AE category.

Preferred terms are sorted in descending frequency, as reported in the ranibizumab 0.5 mg (group I) column.

AE, adverse event; IOP, intraocular pressure; URTI, upper respiratory tract infection; VA, visual acuity; vPDT, verteporfin photodynamic therapy